Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer.

Autor: Singhi EK; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mott F; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Worst M; Medscape Oncology, New York, NY 10014, USA., Leung CH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Carter B; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Presley CJ; Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jazyk: angličtina
Zdroj: Oncology letters [Oncol Lett] 2023 May 03; Vol. 25 (6), pp. 262. Date of Electronic Publication: 2023 May 03 (Print Publication: 2023).
DOI: 10.3892/ol.2023.13848
Abstrakt: Immunotherapy is an effective and generally well-tolerated treatment strategy for older adult patients (aged ≥70 years) with advanced non-small cell lung cancer (NSCLC). Unfortunately, most patients who receive immunotherapy eventually exhibit disease progression during treatment. The present study reports on a subset of older adult patients with advanced NSCLC who could effectively continue immunotherapy beyond radiographic disease progression due to perceived clinical benefit. Local consolidative radiotherapy may be used in select older adult patients to prolong the duration of immunotherapy they receive, with a particular consideration of their preexisting co-morbidities, performance status and tolerance of potential toxicities associated with combined modality therapy. However, prospective research is needed to determine which patients benefit most from the addition of local consolidative radiotherapy, including whether type of disease progression (i.e., sites of progression, pattern of progression) and/or extent of consolidation offered (i.e., complete or incomplete) impact clinical outcomes. Further research is also warranted to determine which patients would most benefit from the continuation of immunotherapy beyond documented radiographic disease progression.
Competing Interests: MW is an employee of Medscape, LLC, New York, NY. JVH has served on the scientific advisory boards for AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, Pneuma Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, RefleXion, and Chugai Pharmaceuticals. He receives research support from AstraZeneca, Bristol-Myers Squibb, Spectrum, and Takeda and royalties and licensing fees from Spectrum outside of the submitted work. MA received research funding (to institution) from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab, and Gilead and receives consultant and advisor fees from GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, and AstraZeneca. He receives speaker fees from AstraZeneca, Nektar Therapeutics, and SITC and acknowledges participation in safety review committees for Nanobiotix-MDA alliance and Hengenix outside of the submitted work. The remaining authors declare no conflict of interest.
(Copyright © 2023, Spandidos Publications.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje